Abstract
IntroductionAdalimumab is effective for maintenance of remission in patients with Crohn’s disease (CD) at a dose of 40 mg subcutaneously every 2 weeks. However, adalimumab is associated with (long-term) adverse...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have